This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Newborn screening (NBS) has become an integral part of many public health programs.1 NBS programs have minimized patient suffering which results from extended...
Kirsten Axelsen moderates the PhRMA-sponsored panel session titled “Progress or Regress…How does CMS’ Maximum Fair Price Negotiation align with...
CRA is a proud sponsor of the MAPS organization. Ayushman Ghosh and Michelle Guo host the roundtable discussion titled “Strategic applications of Machine...
